Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

4 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Durvalumab after Sequential High Dose Chemoradiotherapy versus Standard of Care (SoC) for Stage III NSCLC: A Bi-Centric Trospective Comparison Focusing on Pulmonary Toxicity.
Wass R, Hochmair M, Kaiser B, Grambozov B, Feurstein P, Weiß G, Moosbrugger R, Sedlmayer F, Lamprecht B, Studnicka M, Zehentmayr F. Wass R, et al. Among authors: feurstein p. Cancers (Basel). 2022 Jun 30;14(13):3226. doi: 10.3390/cancers14133226. Cancers (Basel). 2022. PMID: 35804997 Free PMC article.
Results of the Austrian National Lung Cancer Audit.
Burghuber OC, Kirchbacher K, Mohn-Staudner A, Hochmair M, Breyer MK, Studnicka M, Mueller MR, Feurstein P, Schrott A, Lamprecht B, Eckmayr J, Renner F, Bolitschek J, Pohl W, Schenk P, Errhalt P, Cerkl P, Baumgartner B, Kneussl M, Hartl S. Burghuber OC, et al. Among authors: feurstein p. Clin Med Insights Oncol. 2020 Sep 10;14:1179554920950548. doi: 10.1177/1179554920950548. eCollection 2020. Clin Med Insights Oncol. 2020. PMID: 32963472 Free PMC article.
Durvalumab impacts progression-free survival while high-dose radiation >66 Gy improves local control without excess toxicity in unresectable NSCLC stage III: Real-world data from the Austrian radio-oncological lung cancer study association registry (ALLSTAR).
Zehentmayr F, Feurstein P, Ruznic E, Langer B, Grambozov B, Klebermass M, Hüpfel H, Feichtinger J, Minasch D, Heilmann M, Breitfelder B, Steffal C, Gastinger-Grass G, Kirchhammer K, Kazil M, Stranzl H, Dieckmann K; ALLSTAR group. Zehentmayr F, et al. Among authors: feurstein p. Radiother Oncol. 2024 Apr 21;196:110294. doi: 10.1016/j.radonc.2024.110294. Online ahead of print. Radiother Oncol. 2024. PMID: 38653380 Free article.